Stage A
Stage B
Stage C
Stage D
AUC (95% CI)
p value
Sensitivity (%) at 95% specificity
AUC (95% CI)
p value
Sensitivity (%) at 95% specificity
AUC (95% CI)
p value
Sensitivity (%) at 95% specificity
AUC (95% CI)
p value
Sensitivity (%) at 95% specificity
IL8
0.50 (0.34 - 0.67)
0.970
10
0.67 (0.55 - 0.80)
0.013
24
0.77 (0.65 - 0.88)
<0.0001
53
0.82 (0.60 - 1.05)
0.004
75
Mac2BP
0.64 (0.48 - 0.80)
0.073
29
0.66 (0.53 - 0.79)
0.022
38
0.71 (0.59 - 0.84)
0.001
39
0.68 (0.47 - 0.89)
0.112
25
TIMP1 (plasma)
0.62 (0.47 - 0.77)
0.115
23
0.66 (0.53 - 0.78)
0.018
36
0.63 (0.49 - 0.77)
0.047
39
0.65 (0.48 - 0.82)
0.132
20
OPN
0.51 (0.34 - 0.68)
0.900
24
0.73 (0.61 - 0.84)
0.001
42
0.52 (0.38 - 0.66)
0.761
16
0.73 (0.50 - 0.95)
0.023
60
TIMP1 (serum)
0.54 (0.37 - 0.70)
0.631
25
0.68 (0.56 - 0.81)
0.006
28
0.70 (0.58 - 0.83)
0.002
37
0.53 (0.30 - 0.76)
0.751
30
IL6
0.65 (0.50 - 0.81)
0.047
30
0.71 (0.59 - 0.83)
0.003
24
0.74 (0.63 - 0.86)
0.0003
30
0.62 (0.39 - 0.85)
0.281
13
M65
0.64 (0.50 - 0.79)
0.057
38
0.54 (0.42 - 0.68)
0.468
10
0.75 (0.65 - 0.86)
0.0002
25
0.77 (0.57 - 0.96)
0.008
50
IGFBP2
0.63 (0.48 - 0.78)
0.087
29
0.71 (0.60 - 0.82)
0.001
23
0.59 (0.47 - 0.72)
0.160
21
0.88 (0.78 - 0.97)
0.0002
40
TIMP2 (serum)
0.65 (0.49 - 0.81)
0.047
28
0.53 (0.37 - 0.68)
0.692
28
0.55 (0.41 - 0.68)
0.462
15
0.69 (0.48 - 0.91)
0.054
40
TIMP2 (plasma)
0.55 (0.40 - 0.72)
0.442
24
0.54 (0.04 - 0.68)
0.590
29
0.53 (0.40 - 0.67)
0.609
12
0.59 (0.37 - 0.81)
0.372
30
IGF2
0.66 (0.50 - 0.82)
0.035
29
0.56 (0.42 - 0.69)
0.382
19
0.71 (0.59 - 0.82)
0.001
27
0.68 (0.49 - 0.87)
0.074
10
VEGFA
0.58 (0.43 - 0.74)
0.262
14
0.76 (0.64 - 0.88)
<0.0001
40
0.67 (0.55 - 0.79)
0.010
13
0.64 (0.45 - 0.84)
0.159
20
CEACAM6
0.50 (0.35 - 0.65)
0.970
14
0.52 (0.39 - 0.65)
0.766
20
0.59 (0.47 - 0.72)
0.149
19
0.84 (0.70 - 0.97)
0.001
50
TGFB1
0.66 (0.52 - 0.80)
0.029
19
0.72 (0.60 - 0.83)
0.001
32
0.63 (0.51 - 0.76)
0.047
16
0.51 (0.29 - 0.07)
0.940
18
TNF-alpha
0.52 (0.37 - 0.67)
0.778
10
0.65 (0.52 - 0.78)
0.032
21
0.54 (0.41 - 0.68)
0.537
21
0.69 (0.48 - 0.91)
0.082
38
PKM2
0.65 (0.50 - 0.79)
0.051
19
0.67 (0.55 - 0.79)
0.010
16
0.72 (0.60 - 0.83)
0.001
15
0.79 (0.63 - 0.94)
0.004
40
Dkk3
0.51 (0.36 - 0.67)
0.821
0
0.52 (0.38 - 0.65)
0.789
10
0.52 (0.38 - 0.65)
0.820
21
0.57 (0.34 - 0.80)
0.475
30
MMP1
0.56 (0.40 - 0.73)
0.399
14
0.62 (0.49 - 0.75)
0.065
16
0.64 (0.52 - 0.77)
0.029
15
0.61 (0.42 - 0.81)
0.258
10
M30
0.54 (0.38 - 0.70)
0.600
14
0.62 (0.49 - 0.74)
0.080
19
0.63 (0.51 - 0.75)
0.041
12
0.60 (0.39 - 0.81)
0.321
30
MMP8
0.54 (0.38 - 0.69)
0.642
6
0.54 (0.41 - 0.67)
0.544
17
0.54 (0.41 - 0.66)
0.577
12
0.70 (0.49 - 0.91)
0.056
22
ENA-78
0.60 (0.46 - 0.75)
0.172
14
0.59 (0.37 - 0.64)
0.956
7
0.50 (0.37 - 0.63)
1.000
6
0.62 (0.43 - 0.80)
0.250
20
MIP-1beta
0.59 (0.44 - 0.73)
0.260
5
0.52 (0.39 - 0.65)
0.769
7
0.57 (0.45 - 0.70)
0.268
9
0.60 (0.40 - 0.80)
0.307
20
MMP3
0.51 (0.34 - 0.67)
0.950
14
0.55 (0.41 - 0.68)
0.466
10
0.53 (0.40 - 0.66)
0.696
12
0.69 (0.55 - 0.84)
0.054
10
MCP1
0.57 (0.43 - 0.72)
0.329
14
0.52 (0.39 - 0.64)
0.815
3
0.58 (0.46 - 0.71)
0.201
12
0.55 (0.34 - 0.77)
0.592
20
Table 4:
Biomarker sensitivity at 95% specificity according to disease stage.
